The question of whether the activation of SOCs (store-operated Ca 2+ channels) requires the whole or part of the ER (endoplasmic reticulum) has not been fully resolved. The role of a putative sub-compartment of the ER in SOC activation in liver cells was investigated using ectopically expressed TRPV1 (transient receptor potential vanilloid 1), a non-selective cation channel, and TDCA (taurodeoxycholic acid), an activator of SOCs, to release Ca 2+ from different regions of the ER. TRPV1 was expressed in the ER and in the plasma membrane. The amount of Ca 2+ released from the ER by a TRPV1 agonist, measured using fura-2, was the same as that released by a SERCA (sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase) inhibitor, indicating that TRPV1 agonistsensitive stores substantially overlap with SERCA inhibitor-sensitive stores. In contrast with SERCA inhibitors, TRPV1 agonists did not activate store-operated Ca 2+ entry. These findings were confirmed by patch-clamp recording. Using FFP-18, it was shown that SERCA inhibitors release Ca 2+ from the ER located closer to the plasma membrane than the region from which TRPV1 agonists release Ca 2+ . In contrast with SERCA inhibitors, TRPV1 agonists did not induce a redistribution of STIM1 (stromal interaction molecule 1). TDCA caused the release of Ca 2+ from the ER, which was detected by FFP-18 but not by fura-2, and a redistribution of STIM1 to puncta similar to that caused by SERCA inhibitors. It is concluded that in liver cells, Ca 2+ release from a small component of the ER located near the plasma membrane is required to induce STIM1 redistribution and SOC activation.
INTRODUCTION
Hormone-induced increases in the concentration of Ca 2+ in the cytoplasmic space ([Ca 2+ ] cyt ) play a central role in intracellular signalling in animal cells [1] . In liver cells, one of the first types of animal cell in which oscillations in [Ca 2+ ] cyt were observed [2] , hormone-induced oscillations in [Ca 2+ ] cyt regulate pathways of intermediary and xenobiotic metabolism, bile acid secretion, cell proliferation, and apoptosis and necrosis [3] . There is some evidence to indicate that the maintenance of hormone-induced Ca 2+ oscillations in liver cells requires the replenishment of the ER (endoplasmic reticulum) Ca 2+ stores by Ca 2+ entering the cell through SOCs (store-operated Ca 2+ channels) [4, 5] . The question of which Ca 2+ entry pathway(s) is responsible for refilling the ER during hormone-induced Ca 2+ signalling in animal cells is not fully resolved [6] . Rat liver cells express only one type of SOC with a high selectivity for Ca 2+ and properties essentially indistinguishable from those of CRAC (Ca 2+ release-activated Ca 2+ ) channels in mast cells and lymphocytes [7] [8] [9] . The pore of the Ca 2+ -selective SOC is composed of a member of the Orai (CRACM) polypeptide family (reviewed in [10] ), whereas the Ca 2+ sensor in the ER is composed of STIM1 (stromal interaction molecule 1) or another member of the STIM family (reviewed in [10] ). It is proposed that the activation of SOCs involves the movement of Orai1 and STIM1 to the junctional ER at the plasma membrane, and the direct or indirect interaction of STIM1 with Orai1 [10] . We have recently shown that STIM1 redistribution is necessary for SOC activation in liver cells [11] .
Integrity of the ER is required for the generation of hormoneinduced Ca 2+ oscillations and for the regulation of Ca 2+ entry through SOCs. In polarized liver cells, type 2 IP 3 Rs [IP 3 (Dmyo-inositol 1,4,5-trisphosphate) receptors] located near the bile canaliculus initiate many hormone-induced oscillations in [Ca 2+ ] cyt [12] . There is some evidence that in liver cells, a small region of the ER enriched in type 1 IP 3 R is required for the activation of SOCs [3, 13, 14] , an idea that is compatible with observations of restricted movement of Ca 2+ through the ER [15, 16] . However, the results of some studies with other cell types indicate that the whole of the ER is required for SOC activation, and show that Ca 2+ can fully diffuse through the lumen of the whole ER [17] [18] [19] . Taken together, these results suggest that different types of animal cells may have evolved different solutions to the question of how the ER is involved in Ca 2+ entry through SOCs.
The aim of the experiments reported in this paper was to investigate whether all, or only a sub-region, of the ER is required for SOC activation in liver cells. This question was investigated using ectopically expressed TRPV1 [TRP (transient receptor potential) vanilloid 1], a non-selective cation channel of the TRP family, and the choleretic bile acid TDCA (taurodeoxycholic Abbreviations used: BODIPY ® , 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; [Ca 2+ ] cyt , cytoplasmic free Ca 2+ concentration; Ca 2+ ext , extracellular Ca 2+ ; DBHQ, 2,5-di-(tert)-butyl-1,4-benzohydro-quinone; DMEM, Dulbecco's modified Eagle's medium; ER, endoplasmic reticulum; GFP, green fluorescent protein; IP 3 , D-myo-inositol 1,4,5-trisphosphate; IP 3 R, IP 3 receptor; KRH, Krebs-Ringer-Hepes buffer; RTX, resiniferatoxin; SERCA, sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase; SOC, store-operated Ca 2+ channel; I SOC , Ca 2+ current through liver cell SOCs; STIM1, stromal interaction molecule 1; TDCA, taurodeoxycholic acid; TRP, transient receptor potential; TRPV, TRP vanilloid; YFP, yellow fluorescent protein; EYFP, enhanced YFP. 1 To whom correspondence should be addressed (email greg.barritt@flinders.edu.au).
acid) to release Ca 2+ from different regions of the ER. TRPV1 is localized in the ER as well as the plasma membrane and, in some cell types, TRPV1 agonists release Ca 2+ from much of the ER but do not activate SOCs [20, 21] . In liver cells, TDCA induces the release of Ca 2+ from the ER [22] and activates liver cell SOCs [23] . The results from the present study indicate that, in cells ectopically expressing TRPV1, Ca 2+ released from the ER by TRPV1 agonists can be detected using the Ca 2+ -sensitive fluorescent dye fura-2 but not using FFP-18, which report changes in [Ca 2+ ] cyt in the whole cytoplasmic space and in close proximity to the plasma membrane respectively [24] . The amount of Ca 2+ released from intracellular stores by TRPV1 agonists is similar to that released by SERCA (sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase) inhibitors. However, in contrast with SERCA inhibitors, TRPV1 agonists do not activate Ca 2+ entry through SOCs and do not cause the redistribution of STIM1. Ca 2+ released by TDCA could be detected using FFP-18 but not fura-2. TDCA caused a redistribution of STIM1 and activation of SOCs. The results indicate that only a small region of the ER, which does not express ectopic TRPV1, is required for the activation of SOCs.
EXPERIMENTAL

Materials
DMEM (Dulbecco's modified Eagle's medium), fura-2 and FFP-18 (acetoxymethylesters), goat anti-rabbit Alexa-Fluor ® 647 antibody, Calcium Green 5N, pluronic acid F-127 and BODIPY ® (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) TR-X thapsigargin were obtained from Invitrogen Australia (Mt Waverley, Victoria, Australia); IP 3 , ruthenium red, ionomycin and TDCA were from Sigma Australia; thapsigargin and DBHQ [2,5-di-(tert)-butyl-1,4-benzohydro-quinone] from Sapphire Bioscience (New South Wales, Australia); capsaicin, RTX (resiniferatoxin), and N-vanillylnonamide were from Alexis Biochemical (Lausen, Switzerland); FuGENE TM 6 was from Roche Pharmaceutical (Nutley, NJ, U.S.A.); the pDsRed2-ER plasmid was from Clontech (Mountain View, CA, U.S.A.); and glass coverslips were from Menzel-Glaser (Braunschweig, Germany). AdTrack-CMV-TRPV1, prepared by ligating DNA encoding TRPV1, cloned from mouse nodose ganglia, into the AdTrack-CMV plasmid, was provided by Dr Lei Zhang and Dr S. Brookes (Department of Physiology, Flinders University, Adelaide, Australia). The Cherry-STIM1 plasmid [HRP (horseradish peroxidase)-STIM1], constructed by inserting mCherry after the signal sequence of hSTIM1 then inserting this construct into HRP [25] , was provided by Dr Rich Lewis (Molecular and Cellular Physiology, Stanford University, CA, U.S.A.). The YFP (yellow fluorescent protein)-TRPV1 plasmid, constructed by inserting YFP into the Xba1 and Apa I sites of pcDNA3 vector (Invitrogen) followed by C-terminal fusion of rat TRPV1 with the FLAG epitope of the YFP, was provided by Dr Michael Schaefer (Department of Molecular Pharmacology and Cell Biology, Charite University, Berlin, Germany).
Cell culture
H4-IIE rat liver cells (A.T.C.C. CRL 1548) were plated on No. 1 glass coverslips (12, 22 and 30 mm diameter for immunofluorescence, fura-2 and live cell confocal imaging experiments, respectively) and cultured for 24-72 h in DMEM supplemented with 10 % (v/v) fetal bovine serum, penicillin (100 units/ml), streptomycin (0.1 mg/ml) and 10 mM Hepes in 5 % (v/v) CO 2 at 37
• C, as described previously [7, 8] .
Cell transfection, immunochemistry and fluorescence microscopy
For Ca 2+ imaging and patch-clamp experiments, H4-IIE cells were transfected with Ad-Track-CMV-TRPV1 or Ad-Track-CMV (1 μg) using FuGENE 6, according to the manufacturer's instructions, and incubated at 37
• C for 24-48 h. The AdTrack-CMV-TRPV1 plasmid expresses TRPV1 and GFP (green fluorescent protein) as separate proteins each under the control of the CMV promoter. Cells transfected with the Ad-Track-CMV-TRPV1 plasmid, designated TRPV1(+) cells, were identified by GFP fluorescence. Untransfected cells on the same coverslips, designated TRPV1(−) cells, were used as controls. Cells transfected with empty vector (Ad-Track-CMV) were used as additional controls in some experiments.
For studies of intracellular protein localization, H4-IIE cells were co-transfected (3 μg DNA) with pDsRed2-ER and AdTrack-CMV-TRPV1, pDsRed2-ER and YFP-TRPV1 or Cherry-STIM1 and Ad-Track-CMV-TRPV1 using FuGENE TM 6 , and incubated at 37
• C for 24-48 h. For cells transfected with the Ad-Track-CMV-TRPV1 plasmid, the transfection efficiency (proportion of cells expressing TRPV1) was approx. 10 %. For co-localisation studies employing pDsRed2-ER and BODIPY ® TR-X thapsigargin, cells transfected with the pDsRed2-ER plasmid were incubated with 1 μM BODIPY ® TR-X thapsigargin for 10 min at room temperature (23 • C), then washed twice with KRH (Krebs-Ringer-Hepes buffer; described below). The fluorescence of GFP, YFP, pDsRed2, Cherry, and BODIPY ® TR-X thapsigargin was measured using a Leica SP5 laser-scanning confocal microscope. The excitation/emission wavelengths were: 488/500-550 nm for GFP; 514/520-550 for YFP; and 561/600-650 nm for pDsRed2 Cherry and BODIPY ® TR-X thapsigargin.
To detect TRPV1 by immunofluorescence, cells were fixed for 15 min in 4 % (v/v) paraformaldehyde in PBS and permeabilized in 0.2 % (v/v) Triton X-100 in PBS at room temperature. Fixed cells were blocked for 2 h in 10 % (v/v) normal fetal bovine serum in PBS at room temperature, then washed and incubated overnight at 4
• C with a polyclonal anti-TRPV1 antibody raised in rabbits (Chemicon International) (1/1000) with 1 % (v/v) fetal bovine serum in PBS. The cells were then washed in PBS, and incubated for 2 h at room temperature with Alexa-Fluor ® 647-labelled polyclonal anti-rabbit antibody made in goat (Molecular Probes) (1/1000), washed 5 times with PBS and mounted on glass slides in IMMU-Mount medium (Theomo Shandon, Pittsburg, PA, U.S.A.). Fluorescence was measured at 633/675-750 nm excitation/emission by confocal microscopy. Control samples were prepared by omitting the primary antibody. Control images consistently showed low fluorescence (due to nonspecific binding of the secondary antibody) compared with the samples containing both primary and secondary antibodies. Routinely, the fluorescence of control samples was set to zero.
For the further resolution of YFP-TRPV1, pDsRed2-ER and BODIPY ® TR-X thapsigargin confocal images, de-convolution analysis was performed. A series of images (4-9 in total) of the z plane were captured in the confocal microscope using the 63× water immersion objective (1.2 numeric aperture). The sizes of the images were (μm): 0.045, 0.045 and 0.200 in the x, y and z axes respectively. The images were imported into the AutoDeblur 7.5 software (Auto Quant Imaging, Watervliet, NY, U.S.A.) and a '3D blind de-convolution' analysis was performed. ext , then the medium was changed 5 min before beginning the recording of fluorescence to KRH in which Ca 2+ was omitted and 0.5 mM EGTA included. The fluorescence of fura-2 and FFP-18 was measured at room temperature using a Nikon TE300 Eclipse microscope in conjunction with a Sutter DG-4/OF wavelength switcher, Omega XF04 filter set for fura-2, Photonic Science ISIS-3 ICCD camera and UIC Metafluor software. Fluorescence images at 340 nm and 380 nm excitation were obtained every 20 s using a 40× objective. In cells incubated with FFP-18, it has previously been shown that the dye is inserted into the inner leaflet of the plasma membrane by slow "flip-flop" diffusion [24, 26] . For H4-IIE cells loaded with FFP-18, Ni 2+ was employed in order to confirm that the majority of the FFP-18 is located in the inner leaflet of the membrane bilayer facing the cytoplasmic space. This cation quenches FFP-18 fluorescence but does not rapidly permeate the plasma membrane [26] . In cells loaded with FFP-18, addition of Ni 2+ (1 mM) to incubation medium caused a decrease in fluorescence ratio of approx. 5 %, indicating that more than 95 % of the FFP-18 is located on the cytoplasmic face of the plasma membrane.
Measurement of
Fluorescence ] ER using Calcium Green 5N, H4-IIE cells grown on glass coverslips were incubated at 37
• C with 5 μM Calcium Green 5N acetoxymethylester in KRH containing 0.02 % (v/v) pluronic acid for 1 h, washed twice with KRH, then incubated for a further period of 30 min at room temperature to allow de-esterification of the acetoxymethylester. The incubation medium was then changed to a 'cytoplasmic' medium composed of 140 mM KC1, 5 mM NaCl, 7 mM MgSO 4 , 20 mM Hepes, 1 mM ATP, 10.2 mM EGTA and 1.65 mM CaCl 2 , adjusted to pH 7.0. The free [Ca 2+ ] was estimated to be 100 nM using the BAD (Bound and Determined) programme (S. Brooks, Carelton University, Ottawa, Canada). Since GFP is expressed in TRPV1(+) cells, and the fluorescence emission of GFP overlaps with that of Calcium Green 5N, an image of the cells was taken to identify the TRPV1(+) cells. Digitonin (50 μM) was then added to allow the washing out of GFP and Calcium Green 5N in the cytoplasmic space. The remaining fluorescence, which corresponds to Calcium Green 5N in the ER, was imaged in real time using a Nikon TE300 epifluorescence microscope, a 40× objective lens and a band pass emission Endow GFP filter block (Chroma Technology Corp., Rockingham, VT, U.S.A.) (excitation 470/40 nm and emission 525-550 nm and a 495 LP dichroic mirror). In order to compare fluorescence values from different cells, data were standardized by assigning the baseline fluorescence (F o ) the value of 1. The magnitude (plateau) and the time course (half-life) of Ca 2+ released from the ER by a given agent were determined by fitting a non-linear regression equation (single exponential decay) to the Calcium Green 5N curves using Graphpad Prism.
Electrophysiology
Whole-cell patch-clamping was performed at room temperature using a computer-based patch-clamp amplifier (EPC-9 HEKA Electronics, Germany) and PULSE software (HEKA Electronics) [28] . The bath solution contained 140 mM NaCl, 4 mM CsCl, 10 mM CaCl 2 , 2 mM MgCl 2 , 10 mM glucose and 10 mM Hepes, adjusted to pH 7.4 with NaOH. The internal solution contained 120 mM caesium glutamate, 5 mM CaCl 2 , 5 mM MgCl 2 , 1 mM MgATP, 10 mM EGTA and 10 mM Hepes, adjusted to pH 7.2 with NaOH. SOC activation was initiated by addition of 20 μM IP 3 (Dmyo-inositol 1,4,5-triphosphate hexapotassium salt) to the internal solution. Patch pipettes were pulled from borosilicate glass and fire-polished; pipette resistance ranged between 2-4 M . In order to record the SOC (I SOC ) and TRPV1 currents, voltage ramps between − 138 and + 102 mV were applied every 2 s, starting immediately after achieving the whole-cell configuration. All voltages shown have been corrected for the liquid junction potential of − 18 mV between the bath and electrode solutions (estimated by JPCalc [29] ). The holding potential was − 18 mV throughout. Cell capacitance was compensated automatically by the EPC9 amplifier.
Statistical analysis
Results obtained for [Ca 2+ ] cyt and [Ca 2+ ] ER are expressed as means + − S.E.M. (n = 10 -20 cells for each experiment). Statistical significance was assessed using ANOVA followed by the Bonferroni post hoc test and Student's t test (two tailed). Differences between means were considered significant at P 0.05.
RESULTS
Ectopically expressed TRPV1 co-localizes with the ER and plasma membrane
To determine the intracellular localization of ectopically expressed TRPV1, H4-IIE liver cells were transfected with DNA encoding TRPV1-YFP. TRPV1-YFP was principally located intracellularly, with some at the plasma membrane ( Figure 1A ). Substantial co-localization of TRPV1-YFP with the ER, labelled using DsRed2-ER, was observed ( Figure 1A ). Similar results, indicating co-localization of most of the ectopically expressed TRPV1 with the ER were obtained using BODIPY ® TR-X thapsigargin to label the ER ( Figure 1B) . The results obtained using TRPV1-YFP were confirmed using immunofluorescence to localize ectopically-expressed TRPV1, and DsRed2-ER to identify the ER ( with the detection of TRPV1 mRNA in the HepG2 human liver cell line [30] ).
In cells ectopically expressing TRPV1, the intracellular Ca 2+ store released by RTX overlaps substantially with the SERCA inhibitor-releasable store To determine whether TRPV1 facilitates the release of Ca 2+ from intracellular stores, the TRPV1 agonist RTX was added in the absence of Ca When ionomycin was employed in an alternative strategy to release Ca 2+ from intracellular stores, the amount released by ionomycin in TRPV1(+) cells was also found to be less than that released by the ionophore in TRPV1(−) cells ( Figure 2D ). The amount of Ca 2+ released by ionomycin from TRPV1(+) cells was 133 + − 26 compared with 348 + − 14 nM from TRPV1(−) cells (means + − S.E.M., n = 3-8, P < 0.01, Student's 2-tailed t test). Taken together, these results indicate that, in cells ectopically expressing TRPV1, the stores from which TRPV1 agonists release Ca 2+ overlap substantially with those from which SERCA inhibitors release Ca 2+ , and that in TRPV1(+) cells there is less Ca 2+ in the ER than in TRPV1(−) cells. The difference in the amount of SERCA inhibitor-releasable Ca 2+ in the ER of TRPV1(+) and TRPV1(−) cells is probably due to the constitutive activity of TRPV1 in the ER membrane, resulting in a lower steady-state concentration of Ca 2+ in the ER of TRPV1(+) cells compared with that in TRPV1(−) cells. Thus it has previously been reported that in some other cell types ectopically expressed TRPV1 is constitutively active [31, 32] . This may be due, in part, to the activation of TRPV1 by endogenous signalling molecules [33] .
The ability of RTX to induce Ca 2+ release from the ER was tested directly in experiments performed with cells in which the ER was loaded with the fluorescent Ca 2+ reporter Calcium Green 5N. After incubation with the acetoxymethylester of Calcium Green 5N, the cells were subsequently permeabilized to release any dye located in the cytoplasmic space outside the ER. Figure 3(A) shows images of Calcium Green 5N fluorescence in permeabilized control cells. Thapsigargin caused a decrease in Calcium Green 5N fluorescence, and the subsequent addition of ionomycin caused a further decrease ( Figure 3B ). The decrease caused by ionomycin may be due to the further release of Ca 2+ remaining in the ER after thapsigargin treatment, since the timecourse for the release of Ca 2+ from the ER is quite slow [34] , and/or to Ca 2+ release from other intracellular stores. No change In order to test whether the release of Ca 2+ from the ER induced by TRPV1 agonists can activate SOCs, it was necessary to conduct the experiment in the presence of ruthenium red, an inhibitor of TRPV1 channels [35] which is membraneimpermeant [36] , to inhibit Ca 2+ entry through TRPV1 located on the plasma membrane. Therefore we first tested whether ruthenium red effectively inhibits Ca 2+ entry through TRPV1 without inhibiting TRPV1 agonist-induced release of Ca 2+ from the ER. To confirm that the activation of TRPV1 initiates Ca 2+ entry through TRPV1 channels in the plasma membrane of TRPV1(+) cells, RTX was added to cells in the presence of Ca that ruthenium red inhibits Ca 2+ entry in TRPV1(+) cells. It can be seen (Supplementary Figure S2B) that the RTX-induced increase in [Ca 2+ ] cyt did not rapidly return to the baseline value in TRPV1(+) cells following ruthenium red addition. However, when ruthenium red was added before RTX, [Ca 2+ ] cyt did return to baseline ( Figure 2C ). This suggests that the slow return to baseline following ruthenium red addition after RTX is due to (a) the very large entry of Ca 2+ through TRPV1 channels in the plasma membrane and (b) slow clearance of this Ca 2+ from the cytoplasmic space. The latter may also be slowed by the uptake and subsequent slow release of large amounts of Ca 2+ by the mitochondria.
Ruthenium red did not inhibit the ability of RTX to release Ca 2+ from the ER (Supplementary Figure S2D) . There was no significant difference between the increase in [Ca 2+ ] cyt induced by RTX in TRPV1(+) cells in the presence of ruthenium red and that induced by RTX in the absence of inhibitor. The amounts of Ca 2+ released (peak height) by RTX and by RTX in the presence of ruthenium red were 91 + − 22 and 80 + − 19 nM respectively (means + − S.E.M., n = 5). Results similar to those with RTX were obtained using capsaicin (10 μM) or N-vanillylnonamide (10 μM) in place of RTX, and with TRPV1-YFP in place of TRPV1 (results not shown). These results indicate that, in TRPV1(+) cells, Ca 2+ entry through TRPV1 channels in the plasma membrane is inhibited by ruthenium red, but ruthenium red does not inhibit RTX-induced release of Ca 2+ from the ER. It was also necessary to test whether either ruthenium red or RTX inhibits Ca 2+ entry through SOCs induced by a SERCA inhibitor, and whether ruthenium red inhibits SERCA inhibitorinduced release of Ca 2+ from the ER. These experiments were conducted using TRPV1(−) cells. Neither ruthenium red (compare Supplementary Figure S3B To test whether the release of Ca 2+ from the ER induced by the action of RTX on TRPV1 in the ER can activate Ca 2+ entry through SOCs, TRPV1(+) cells were initially incubated in the absence of Ca 2+ ext . RTX was added to induce Ca 2+ release from the ER through TRPV1, ruthenium red to block Ca 2+ entry through TRPV1 in the plasma membrane, then Ca 2+ ] cyt were 114 + − 11 and 109 + − 9 nM/min (means + − S.E.M., n = 4-13, P > 0.05) in TRPV1(+) and TRPV1(−) cells respectively (means + − S.E.M. for three independent experiments similar to the one shown in Figure 4B ). This comparison of initial rates of Ca 2+ entry in TRPV1(+) and TRPV1(−) cells also provides indirect evidence that, under the experimental conditions employed, ruthenium red completely inhibits Ca 2+ entry through TRPV1 channels in the plasma membrane. If this were not the case, it might be expected that the rate of Ca In confirmation of the results with DBHQ and ionomycin described above, the amount of Ca 2+ released by thapsigargin in TRPV1(−) cells was greater than that released in TRPV1(+) cells ( Figure 4B ). The amount of Ca 2+ released (peak height) by thapsigargin (1 μM) was 84 + − 6 and 161 + − 30 nM for TRPV(+) and TRPV(−) cells respectively (means + − S.E.M. for three independent experiments similar to the one shown in Figure 4B ). Taken together, these results indicate that, in TRPV1(+) cells, release of Ca 2+ from the ER induced by TRPV1 agonists acting on ectopically expressed TRPV1 does not activate Ca 2+ entry through SOCs (compare with [20, 21] Figure 5 ) indicates that, in the presence of RTX, DBHQ causes a large additional increase in Ca 2+ entry, presumably due to the activation of SOCs which are not activated by the addition of RTX alone.
Patch-clamp recording was used to confirm that TRPV1-mediated release of Ca 2+ from the ER does not activate SOCs. Since RTX cannot readily be removed by washing cells, the experiments were conducted using N-vanillylnonamide as the TRPV1 agonist. Addition of N-vanillylnonamide (10 μM) to TRPV1(+) cells induced a large outwardly rectifying current ( Figures 6A and 6B ). When N-vanillylnonamide was washed out, the amplitude of the inward current returned exactly to the baseline value recorded before agonist addition ( Figures 6A, 6C and 6D). The current-voltage plots and the currents recorded in response to − 138 mV steps obtained before and after the application of N-vanillylnonamide overlap each other, suggesting there is no activation of I SOC during depletion of the intracellular Ca 2+ stores caused by the application of N-vanillylnonamide ( Figures 6C and 6D) . The current density in TRPV1(+) cells was − 8.6 + − 0.57 pA/pF before agonist addition and − 8.4 + − 0.89 pA/pF after application of the agonist. In contrast, depletion of the intracellular Ca 2+ stores in TRPV1(+) cells by application of IP 3 through the patch pipette activated a current, I SOC ( Figures 6E and 6F) , typical of that previously described in untransfected liver cells [9, 11] . The average amplitude of I SOC at − 118 mV in these cells was 2.93 + − 0.73 pA/pF (n = 7), which is equal to the average of I SOC obtained in previous studies with non-transfected cells [7] [8] [9] . Current activated by IP 3 showed Ca 2+ -dependent inactivation at − 138 mV ( Figure 6F ) typical of I SOC in H4-IIE cells and hepatocytes [8, 9] , whereas the current remaining after the washout of N-vanillylnonamide showed no inactivation (compare trace 2, Figure 6F , with trace 2, Figure 6D ). Figure 7A ) in contrast with the RTX-induced increase in [Ca 2+ ] cyt detected using fura-2 (e.g. Figure 2A ). The Ca Figure 7A ) and also with thapsigargin ( Figure 7C ). These results indicate that the region of the ER from which RTX (via TRPV1) releases Ca 2+ is further from the plasma membrane than the region from which thapsigargin principally releases Ca 2+ . It was noted that there is some variation in the FFP-18 fluorescence ratio between the experiments shown in Figure 7 , and that, in contrast with results obtained with fura-2, there was no decrease in FFP-18 fluorescence ratio where Ca 2+ ext was reduced from 1.3 mM to zero. The variation in FFP-18 fluorescence may be due to (i) differences in the average amount of FFP-18 inserted into the plasma membrane in the correct orientation between different experiments, and (ii) variations in the concentration of FFP-18 in the plasma membrane in the different regions of the plasma membrane. The difference in responses of fura-2 and FFP-18 to a decrease in [Ca 2+ ] ext may be due to differences in the distribution of mitochondria and the ER which will take up Ca 2+ in response to an increase in [Ca 2+ ] cyt in the space immediately under the plasma membrane and in the deeper cytoplasmic space, and to differences in the kinetics of interaction of Ca 2+ with fura-2 and FFP-18.
Ca
2+ release mediated by ectopically expressed TRPV1 does not cause a redistribution of STIM1
It has previously been shown that STIM1 is expressed in liver cells and is required for the activation of SOCs [11] . Studies with other cell types have shown that the release of Ca 2+ from the ER induced by SERCA inhibitors is associated with a relocalization of some STIM1 to ER-plasma membrane junctions [38] [39] [40] . This redistribution of STIM1 is a necessary step in the activation of SOCs [10] . We investigated whether RTX would induce a redistribution of STIM1 in TRPV1(+) cells. Since cells transfected with TRPV1 also express GFP, the experiments were conducted by co-transfecting the cells with Cherry-STIM1 to monitor the distribution of STIM1. We first investigated the distribution of STIM1 in relation to the ER in control (untransfected) cells. In cells co-transfected with DNA encoding Cherry-STIM1 and pEYFP-ER [encoding EYFP (enhanced YFP) targeted to the ER by the KDEL sequence], Cherry-STIM1 colocalized with ER-targeted EYFP as indicated by the merged image ( Figure 8A ). This figure shows a confocal image of a cell taken in a z-plane at the middle of the cell. The outline of the nucleus, which does not contain ER or STIM1, is evident. These results indicate that STIM1 is principally located in the ER.
The ability of RTX to induce a redistribution of STIM1 in TRPV(+) cells was compared with that of thapsigargin. Thapsigargin induced a redistribution of STIM1 to a punctate pattern in essentially all TRPV1(+) cells examined ( Figure 8B , compare thapsigargin with Control) as shown previously for other cell types [38, 41] . Figure 8 We have previously shown that the choleretic bile acid TDCA activates Ca 2+ entry through Ca 2+ -selective SOCs in liver cells. The SOCs activated by TDCA were characterized by patch-clamp recording and shown to be identical to the liver cell Ca 2+ -selective SOCs activated by thapsigargin, IP 3 and agonists such as ATP. We also previously showed that TDCA induces the release of Ca 2+ from intracellular stores, monitored using fura-2, in the presence of 2.4 mM Ca 2+ ext and 10 μM Gd 3+ (added to inhibit Ca 2+ entry). However, in the absence of Gd 3+ and at zero Ca 2+ ext , no TDCA-induced release of Ca 2+ from intracellular stores could be detected [23] . This observation was confirmed in the present study by adding TDCA to cells loaded with fura-2 and incubating in the absence of added Ca Figure 9A ). TDCA did not substantially reduce the amount of Ca 2+ released by DBHQ ( Figure 9A , inset). Taken together with the previous observations that TDCA activates Ca 2+ entry through SOCs, these results indicate that the ability of TDCA to activate SOCs is not associated with a detectable release of Ca 2+ from SERCA inhibitor-releasable intracellular Ca 2+ stores in fura-2-loaded cells.
The actions of TDCA at zero Ca 2+ ext were investigated further by conducting the following experiments. In the absence of Ca 2+ ext , TDCA caused a redistribution of STIM1 to give a punctate pattern similar to that induced by thapsigargin (Figure 10 ). While the effect of TDCA was slower in onset than that caused by thapsigargin, the resulting pattern of STIM1 localisation was similar to that induced by thapsigargin (Figure 10 ). Since a redistribution of STIM1 is thought to be caused by Ca 2+ release from the ER [10, 11] , the results shown in Figure 10 indicate that, in the absence of Ca 2+ ext , TDCA induces the release of some Ca 2+ from the ER, even though this cannot be detected by fura-2 as indicated in the experiment in Figure 9 (A). We therefore tested whether any Ca 2+ release from the ER induced by TDCA in the absence of Ca 2+ ext could be detected using FFP-18, which should detect an increase in [Ca 2+ ] cyt close to the plasma membrane [24, 37] . In cells incubated in the absence of Ca 2+ ext , a transient increase in [Ca 2+ ] cyt was observed using FFP-18 ( Figure 9B ). Subsequent addition of DBHQ caused a further transient increase in [Ca 2+ ] cyt ( Figure 9B ). The ability of TDCA to induce the release of some Ca 2+ from the ER was confirmed using cells loaded with Calcium Green 5N and subsequently permeabilized to monitor the amount of Ca 2+ in the ER as described above. TDCA caused a small decrease in the fluorescence of Calcium Green 5N ( Figure 3D) . A non-linear regression equation (single exponential release from a small region of the ER near the plasma membrane, and this is necessary and sufficient to activate SOCs.
DISCUSSION
The main new findings reported in the present paper can be summarized as follows. In cells ectopically expressing TRPV1, the amount of Ca 2+ released from the ER by TRPV1 agonists was the same as that released by SERCA inhibitors, indicating that the Ca 2+ stores released by TRPV1 agonists and SERCA inhibitors substantially overlap. However, in contrast with the actions of SERCA inhibitors, TRPV1 agonists did not activate SOCs or cause a redistribution of STIM1. Moreover, SERCA inhibitors released Ca 2+ from a region of the ER closer to the plasma membrane than the region of the ER from which TRPV1 agonists released Ca 2+ , as indicated by the results obtained using FFP-18. Using TDCA, an activator of SOCs, and zero Ca 2+ ext , it was possible to release Ca 2+ from a region of the ER close to the plasma membrane without releasing Ca 2+ from the bulk of the ER. These actions of TDCA were associated with a redistribution of STIM1. In addition, it was found that the amount of Ca 2+ stored in the ER of cells ectopically expressing TRPV1 was less than that in control cells. These results provide evidence that the activation of SOCs in liver cells requires Ca 2+ release from a small region of the ER close to the plasma membrane, and that Ca 2+ release from the bulk of the ER is not necessary for SOC activation.
The results obtained using TRPV1-YFP and immunofluorescence together with confocal fluorescence microscopy indicate that, while some ectopically expressed TRPV1 is at the plasma membrane, the TRPV1 is predominately found in the ER. The observations that, when expressed ectopically in liver cells, TRPV1-YFP facilitates Ca 2+ movement across the plasma and ER membranes in a manner similar to TRPV1, indicate that TRPV1-YFP functions in the same way as TRPV1 in liver cells, and is likely to be localized to the same sites as TRPV1. Further evidence for a predominately ER localization of TRPV1 comes from the observation that TRPV1 agonists release the same amount of intracellular Ca 2+ as that released by SERCA inhibitors. Two TRPV1 agonists to TRPV1(+) cells did not activate Ca 2+ entry, assessed using fura-2 and the Ca 2+ add-back assay. In control experiments, neither ruthenium red nor RTX blocked SERCA inhibitor-activated Ca 2+ entry through SOCs.
(ii) The SERCA inhibitor DBHQ caused substantial additional Ca 2+ entry in TRPV1(+) cells (assessed using the fura-2 and Ca 2+ addback assay), over and above that induced by RTX. (iii) In patchclamp recording experiments with TRPV1(+) cells, no inward current with the properties of the liver cell SOC could be detected following addition of the TRPV1 agonist N-vanillylnonamide. (iv) In TRPV1(+) cells, TRPV1 agonists did not induce the redistribution of STIM1, whereas SERCA inhibitors induced a redistribution of STIM1 similar to that observed in other cell types. Moreover, it has previously been shown that the redistribution of STIM1 induced by SERCA inhibition is a necessary step in the activation of SOCs in several types of cells, including liver cells [10, 11] .
The amount of Ca 2+ in the ER in TRPV1(+) cells was less than that in the ER of TRPV1(−) cells, most likely due to constitutive activity of TRPV1 in the ER membrane [31] [32] [33] [42] [43] [44] . There was no evidence from either fura-2 or patch-clamp experiments that the lower ER Ca 2+ in TRPV1(+) cells caused a constitutive activation of SOCs. Moreover, it was possible to activate Ca 2+ entry through SOCs with SERCA inhibitors in TRPV1(+) cells, in a manner similar to that for TRPV1(−) cells.
In TRPV1(+) cells, TRPV1 agonists released Ca 2+ from an intracellular Ca 2+ store which overlaps substantially with the SERCA inhibitor-sensitive store. However, TRPV1 agonists did not activate SOCs or induce a redistribution of STIM1. These observations indicate that the intracellular Ca 2+ store required for activation of SOCs is a small component of the ER, and does not contain TRPV1. Some indication of the nature of the ER subcomponent responsible for SOC activation was obtained from the results of experiments conducted with TDCA. We showed previously that in liver cells TDCA activates SOCs which are identical to those activated by IP 3 and thapsigargin. In cells incubated in the absence of Ca 2+ ext , we could not detect a TDCAinduced release of Ca 2+ from the ER using fura-2, yet under these conditions TDCA did cause a redistribution of STIM1 similar to that caused by SERCA inhibitors. This last result suggests that TDCA does cause Ca 2+ release from the ER, but fura-2 failed to detect it. Thus TDCA may release Ca 2+ from a small sub-region of the ER required for SOC activation.
These ideas are consistent with results obtained using FFP-18. In TRPV1(+) cells, the release of Ca 2+ induced by TRPV1 agonists was detected by fura-2, but not by FFP-18, which detects Ca 2+ near the plasma membrane [24, 26] . In contrast, Ca 2+ release induced by TDCA could be detected by FFP-18 but not by fura-2, although both FFP-18 and fura-2 detected Ca 2+ release induced by SERCA inhibitors. These results suggest that the putative sub-region of the ER from which TDCA releases Ca 2+ is near the plasma membrane, whereas the region of ER from which TRPV1 agonists release Ca 2+ [in TRPV1(+) cells] is located further from the plasma membrane. An additional implication is that luminal Ca 2+ in the ER sub-region responsible for SOC activation exchanges slowly with luminal Ca 2+ in the rest of the ER.
We do not yet know why TRPV1 is localized in some but not all of the ER. Further experiments will be required to investigate this. The mechanisms by which TRP proteins are targeted to different intracellular locations are complex and not yet fully understood [45] . Moreover, numerous previous studies of different cell types have provided evidence that the ER is heterogeneous, and that proteins involved in Ca 2+ signalling, including IP 3 and ryanodine receptors and SERCA, can be heterogeneously localized in the ER [46] .
The idea that a small region of the ER (or another intracellular organelle) is required for the activation of the SOCs in liver cells is consistent with conclusions reached from previous studies with rat hepatocytes which employed adenophostin A, an IP 3 receptor agonist with high affinity for IP 3 R, and IP 3 agonists with different affinities for type 1 and type 2 IP 3 Rs [13, 14] . Studies with some other cell types also provide evidence that Ca 2+ release from a small region of the ER is sufficient for SOC activation [6, [47] [48] [49] . A recent study in human salivary gland cells compared the abilities of two concentrations of thapsigargin (1.0 nM and 1.0 μM) to release Ca 2+ from the ER and activate Ca 2+ entry. The results provide evidence that only a small component of the thapsigarginsensitive intracellular Ca 2+ store is required to activate SOCs in this cell type, and that this ER component is in close proximity to the plasma membrane [50] . The results of previous experiments conducted with DT40B lymphocytes and ectopically expressed STIM1-GFP indicate that, although the bulk of STIM1 is located in the ER, some is localized in a sub-compartment, possibly comprised of mobile vesicles. When Ca 2+ stores are depleted these vesicles accumulate just below the plasma membrane and are responsible for activation of SOCs [38] . Moreover, there is evidence to suggest that the critical movement of STIM1 in the ER during the activation of Orai1 in the plasma membrane takes place in close proximity to the plasma membrane at the ERplasma membrane junctions [39, 40] .
In conclusion, the present results provide evidence that Ca 
